REVVITY, INC.

RVTY 10-K · Q4 2025
API behind this page

RVTY Q4 2025 request

Playground key active
Request URL /api/financials?ticker=RVTY&year=2025&quarter=4
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q4 2025 Q4 2024 YoY
Revenue 772,056 729,372 +5.9%
Show Product Lines breakouts
Product 647,001 620,284 +4.3%
Service 125,055 109,088 +14.6%
Show Business Segments breakouts
Diagnostics [Member] 390,067 354,610 +10.0%
Diagnostics [Member] · Americas 129,055 125,262 +3.0%
Diagnostics [Member] · Asia 123,710 119,972 +3.1%
Diagnostics [Member] · Europe 137,302 109,376 +25.5%
Diagnostics [Member] · Immunodiagnostics [Member] 240,789 215,148 +11.9%
Diagnostics [Member] · Reportable Segment Revenue [Member] 390,067 354,610 +10.0%
Diagnostics [Member] · Reproductive health [Member] 149,278 139,462 +7.0%
Life Sciences [Member] 381,989 374,762 +1.9%
Life Sciences [Member] · Americas 191,420 193,363 -1.0%
Life Sciences [Member] · Asia 90,714 93,349 -2.8%
Life Sciences [Member] · Europe 99,855 88,050 +13.4%
Life Sciences [Member] · Life Sciences Solutions [Member] 319,682 312,953 +2.2%
Life Sciences [Member] · Reportable Segment Revenue [Member] 381,989 374,762 +1.9%
Life Sciences [Member] · Software [Member] 62,307 61,809 +0.8%
Show Geography breakouts
Americas 320,475 318,625 +0.6%
Asia 214,424 213,321 +0.5%
Europe 237,157 197,426 +20.1%
Show Major goods/service lines [Axis] breakouts
Immunodiagnostics [Member] 240,789 215,148 +11.9%
Life Sciences Solutions [Member] 319,682 312,953 +2.2%
Reproductive health [Member] 149,278 139,462 +7.0%
Software [Member] 62,307 61,809 +0.8%
Show Segment Reporting [Axis] breakouts
Reportable Segment Revenue [Member] 772,056 729,372 +5.9%
Cost of Revenue (Q) — — —
Show Product Lines breakouts
Product 303,254 271,553 +11.7%
Service 47,143 45,529 +3.5%
Selling, General & Administrative 251,734 244,332 +3.0%
Research & Development 58,176 49,208 +18.2%
Operating Income 111,749 118,750 -5.9%
Interest And Other Expense Net 20,189 24,192 -16.5%
Income Before Taxes 91,560 94,558 -3.2%
Income Tax Expense (Benefit) -4,211 6,175 -168.2%
Income Loss From Continuing Operations 95,771 88,383 +8.4%
Income Loss From Discontinued Operations Net Of Tax 2,593 6,262 -58.6%
Net Income 98,364 94,645 +3.9%
Income Loss From Continuing Operations Per Basic Share 0.84 0.73 +15.1%
Income Loss From Discontinued Operations Net Of Tax Per Basic Share 0.02 0.05 -60.0%
EPS (Basic) 0.86 0.78 +10.3%
Income Loss From Continuing Operations Per Diluted Share 0.84 0.72 +16.7%
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share 0.02 0.05 -60.0%
EPS (Diluted) 0.86 0.78 +10.3%
Non-Operating Income (Expense) -20,189 -24,192 +16.5%
Interest Expense 23,513 22,781 +3.2%
Interest Income -5,752 -9,828 +41.5%
Comprehensive Income 56,034 -69,545 +180.6%
Wtd Avg Shares (Basic) -1,144 -442 -158.8%
Wtd Avg Shares (Diluted) -1,140 -514 -121.8%

Balance Sheet

Balance Sheet
Metric Q4 2025 Q4 2024 YoY
Current Assets
Cash & Cash Equivalents 919,860 1,163,396 -20.9%
Accounts Receivable 744,671 632,400 +17.8%
Inventory 379,497 367,587 +3.2%
Other Assets Current 195,719 186,225 +5.1%
Total Current Assets 2,239,747 2,349,608 -4.7%
Non-Current Assets
Property, Plant & Equipment 479,249 482,217 -0.6%
Operating Lease Right-of-Use Assets 165,439 167,716 -1.4%
Goodwill 6,613,493 6,463,619 +2.3%
Show Business Segments breakouts
Diagnostics [Member] 1,868,531 1,922,152 -2.8%
Life Sciences [Member] 4,744,962 4,541,467 +4.5%
Other Non-Current Assets 323,480 288,397 +12.2%
Total Assets 12,168,411 12,392,478 -1.8%
Intangible Assets 2,347,003 2,640,921 -11.1%
Show Finite and Indefinite Lived Intangible Assets by Major Class [Axis] breakouts
Core Technology [Member] 703,600 826,299 -14.8%
Customer Relationships 1,586,754 1,749,034 -9.3%
Licensing Agreements 7,712 9,309 -17.2%
Patents 1,068 1,515 -29.5%
Trade Names And Trademarks [Member] 47,869 54,764 -12.6%
Marketable Securities (Non-Current) 27,956 27,413 +2.0%
Other Assets
Intangible Assets Net Excluding Goodwill 2,347,003 2,640,921 -11.1%
Current Liabilities
Other Long Term Debt Current 588,828 242 +243217.4%
Accounts Payable 185,464 167,463 +10.7%
Accrued Liabilities 556,954 485,395 +14.7%
Total Current Liabilities 1,331,246 653,100 +103.8%
Deferred Revenue 160,194 140,212 +14.3%
Current Portion of Long-Term Debt 588,828 242 +243217.4%
Show Fair Value Hierarchy breakouts
Fair Value Inputs Level2 · 1.875 Percent Ten Year Senior Unsecured Notes [Member] 588,828 — —
Non-Current Liabilities
Long-Term Debt 2,631,236 3,150,476 -16.5%
Other Non-Current Liabilities 807,461 770,523 +4.8%
Operating Lease Liabilities 148,108 151,505 -2.2%
Total Liabilities 4,918,051 4,725,604 +4.1%
Long-Term Debt (Q) — — —
Show Fair Value Hierarchy breakouts
Fair Value Inputs Level2 2,631,236 3,150,476 -16.5%
Fair Value Inputs Level2 · 1.900% Senior Unsecured Notes due 2028 498,061 497,392 +0.1%
Fair Value Inputs Level2 · 2.250% Senior Unsecured Notes due in 2031 496,440 495,876 +0.1%
Fair Value Inputs Level2 · 2.55 Percent Senior Unsecured Notes due in 2031 397,973 397,618 +0.1%
Fair Value Inputs Level2 · 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] 845,596 844,542 +0.1%
Fair Value Inputs Level2 · 3.625 Percent Senior Unsecured Notes due in 2051 396,023 395,937 0.0%
Fair Value Inputs Level2 · Senior Unsecured Notes 3,222.9 3,151.5 +2.3%
Show Debt Instrument breakouts
Line of Credit, Maturing January 7, 2030 2,857 — —
Stockholders' Equity
Common Stock 112,281 120,646 -6.9%
Additional Paid In Capital Common Stock 1,305,900 2,097,110 -37.7%
Retained Earnings 6,054,314 5,845,223 +3.6%
Accumulated Other Comprehensive Income -222,135 -396,105 +43.9%
Total Stockholders' Equity 7,250,360 7,666,874 -5.4%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -222,135 -396,105 +43.9%
Additional Paid In Capital 1,305,900 2,097,110 -37.7%
Common Stock 112,281 120,646 -6.9%
Retained Earnings 6,054,314 5,845,223 +3.6%
Total Liabilities & Equity 12,168,411 12,392,478 -1.8%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q4 2025 YTD Q4 2024 YoY
Operating Activities
Depreciation & Amortization 103,079 105,033 -1.9%
Stock-Based Compensation -4,071 5,053 -180.6%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 -1,341 -7,875 +83.0%
Amortization Of Financing Costs And Discounts 992 1,022 -2.9%
Foreign Currency Transaction Gain Loss Unrealized 51 4 +1175.0%
Change in Accounts Receivable -59,380 -49,260 -20.5%
Change in Inventory 2,289 18,269 -87.5%
Change in Accounts Payable 7,075 -1,243 +669.2%
Increase Decrease In Accrued Liabilities And Other Operating Liabilities 51,105 92,839 -45.0%
Net Cash Provided By Used In Operating Activities Continuing Operations 181,960 175,467 +3.7%
Cash Provided By Used In Operating Activities Discontinued Operations 0 -1,237 +100.0%
Net Cash from Operations 181,960 174,230 +4.4%
Investing Activities
Capital Expenditures -20,171 -24,454 +17.5%
Purchases Of Investments And Notes Receivables -356 -2,250 +84.2%
Net Cash Provided By Used In Investing Activities Continuing Operations -20,452 -26,704 +23.4%
Cash Provided By Used In Investing Activities Discontinued Operations 0 9,375 -100.0%
Net Cash from Investing -20,452 -17,329 -18.0%
Financing Activities
Proceeds From Repayments Of Other Debt -363 -822 +55.8%
Share Repurchases -168,285 -185,157 +9.1%
Payments Of Dividends Common Stock -7,955 -8,539 +6.8%
Net Cash from Financing -176,310 -192,990 +8.6%
Other Cash Flow
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 921,030 1,164,452 -20.9%
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 3,257 -30,267 +110.8%
Net Change in Cash -11,545 -66,356 +82.6%
Restricted Cash Current 6 1,056 -99.4%
Restricted Cash Noncurrent 1,164 — —

Values in thousands USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key